Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
Ibrahim Al-ZakwaniMohammad ZubaidAlawi A Alsheikh-AliWael AlmahmeedWafa RashedPublished in: Cardiovascular therapeutics (2018)
Among patients discharged after an ACS event, concurrent EBM prescribing was associated with lower all-cause mortality that persists for up to 12-months posthospital discharge. The relative benefits of EBMs were also consistent across age, GRACE risk score, and discharge diagnosis.
Keyphrases
- primary care
- acute coronary syndrome
- adverse drug
- cardiovascular events
- left ventricular
- risk factors
- locally advanced
- type diabetes
- squamous cell carcinoma
- emergency department
- cardiovascular disease
- stem cells
- heart failure
- radiation therapy
- bone marrow
- drug induced
- atrial fibrillation
- smoking cessation
- replacement therapy